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Abstract. 
 
The 
 
b
 
 
 
chemokine known as 6-C-kine, sec-
ondary lymphoid-tissue chemokine (SLC), TCA4, or 
Exodus-2 (herein referred to as 6CK/SLC) can trigger 
rapid integrin-dependent arrest of lymphocytes rolling 
under physiological shear and is highly expressed by 
high endothelial venules, specialized vessels involved in 
lymphocyte homing from the blood into lymph nodes 
and Peyer’s patches. We show that 6CK/SLC is an ago-
nist for the lymphocyte chemoattractant receptor, 
CCR7 (EBI-1, BLR-2), previously described as a re-
ceptor for the related 
 
b 
 
chemokine MIP-3
 
b
 
 (ELC or 
Exodus-3). Moreover, 6CK/SLC and MIP-3
 
b
 
 attract 
the same major populations of circulating lymphocytes, 
including naive and memory T cells 
 
. 
 
B cells (but not 
natural killer cells); desensitization to MIP-3
 
b
 
 inhibits 
lymphocyte chemotaxis to 6CK/SLC but not to the 
 
a 
 
chemokine SDF-1 (stromal cell–derived factor); and 
6CK/SLC competes for MIP-3
 
b
 
 binding to resting 
mouse lymphocytes. The findings suggest that the 
majority of circulating lymphocytes respond to 6CK/SLC 
and MIP-3
 
b
 
 in large part through their common re-
ceptor CCR7 and that these molecules may be impor-
tant mediators of physiological lymphocyte recircula-
tion in vivo.
 
L
 
ymphocytes
 
 cycle throughout the body and are in con-
stant flux, traveling long distances via the circula-
tion, entering tissues where they may encounter an-
tigens and eventually reentering the circulation. Secondary
lymphoid organs (lymph nodes, Peyer’s patches, and spleen)
are major sites of lymphocyte traffic, as these organs are
specialized for the support of antigen presentation and for
facilitating lymphocyte interactions. Lymphocyte recruit-
ment from the blood into lymph nodes and Peyer’s patches
and into sites of severe chronic inflammation is controlled
by interactions with specialized high endothelial venules
(HEV).
 
1
 
 These interactions are thought to be mediated by
a multistep process, involving in many instances: (
 
1a
 
) teth-
ering of blood borne cells through receptors presented on
microvilli, followed by (
 
1b
 
) rolling along the vessel wall,
(
 
2
 
) rapid activation of lymphocyte integrins, (
 
3
 
) integrin-
dependent adhesion resistant to shear, and (
 
4
 
) diapedesis
(2, 8, 36). The rapid adhesion triggering (step 2) and
transendothelial migration (step 4) are thought to be me-
 
diated by G
 
i
 
a
 
-linked receptors of the chemoattractant
subfamily. Chemoattractant cytokines (chemokines) act
through this class of receptors (1, 30, 40), and it has been
speculated that they mediate these lymphocyte trafficking
events (7, 8, 31, 32). 
In the context of physiological lymphocyte recirculation,
recent studies have focused our attention on two chemo-
kines in particular: the 
 
b 
 
chemokine 6-C-kine or secondary
lymphoid-tissue chemokine (6CK/SLC; also known as TCA4
and Exodus-2) (15, 17, 24, 34), whose receptor has not
been defined, and MIP-3
 
b
 
 
 
(ELC, Exodus-3) (27, 39),
whose receptor is CCR7 (also known as EBI-1 and BLR-
2). Although antibodies to these chemokines remain to be
produced, Northern blot and cDNA library analyses sug-
gest that 6CK/SLC and MIP-3
 
b
 
 are most highly expressed
in lymphoid organs (15, 17, 24, 27, 39). Of particular inter-
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est is the finding that 6CK/SLC message is abundant in
HEV (14), the vessels involved in lymphocyte recruitment
into lymph nodes and Peyer’s patches in vivo, and that
6CK/SLC and MIP-3
 
b
 
 can trigger rapid 
 
b
 
2 integrin activa-
tion in a major proportion of resting human and mouse
lymphocytes, inducing adhesion to ICAM-1 and promot-
ing rapid lymphocyte arrest under physiologic shear (12).
6CK/SLC is also a highly selective chemoattractant for
lymphocytes, attracting naive but also memory T cells and,
to a lesser extent, B cells (14, 17). Although chemotactic
activity of MIP-3
 
b
 
 on resting lymphocytes has not been re-
ported previously, several T cell lines are attracted effi-
ciently to MIP-3
 
b
 
,
 
 
 
and neither 6CK/SLC nor MIP-3
 
b
 
 ap-
pear to act on monocytes or granulocytes (14, 17, 34, 39).
This is an important issue because circulating monocytes
and neutrophils share with lymphocytes the L-selectin and
 
b
 
2 integrin adhesion molecules required for rolling and ar-
rest in lymph node HEVs, leading to the current hypothe-
sis that the adhesion triggering (and potentially chemoat-
tractant) agonists associated with these specialized venules
must be responsible for the highly selective lymphocyte
accumulation observed, and thus must preferentially or
exclusively act on recirculating lymphocytes (18, 19, 36). In
contrast to 6CK/SLC and MIP-3
 
b
 
, message for the other
major chemoattractant for recirculating lymphocytes, stro-
mal cell–derived factor 1
 
a
 
 (SDF-1
 
a
 
), is widely expressed
in diverse tissues (35), and SDF-1 attracts monocytes, nat-
ural killer (NK) cells, and other cell types as well (refer-
ence 5 and vide infra). Other chemokines with reported at-
tractant activity for subsets of circulating lymphocytes,
such as MCP-1 and IL-8, also lack lymphocyte selectivity,
displaying prominent chemoattractant activities for mye-
loid or monocytic cells (1, 28, 30).
Here we report that the HEV-expressed chemokine
6CK/SLC signals through the MIP-3
 
b
 
 receptor CCR7.
Moreover, the same major lymphocyte subpopulations
that chemotax to 6CK/SLC also migrate to MIP-3
 
b
 
, and
desensitization of resting lymphocytes to MIP-3
 
b
 
 inhibits
their responses to 6CK/SLC, as well. We propose that,
along with the specialized adhesion/homing receptors in-
volved, 6CK/SLC, MIP-3
 
b
 
, and their common receptor
CCR7 may play an important role in the physiological re-
circulation and homing of lymphocytes.
 
Materials and Methods
 
Preparation of Human and Mouse Lymphocytes
 
Human peripheral blood was collected in heparinized tubes from healthy
donors. Granulocytes were removed as described (25). Monocytes were
removed by two 30-min rounds of adherence to a culture flask (model
T-175; Nunc, Roskilde, Denmark) at 37
 
8
 
C and 8% CO
 
2
 
 in RPMI 1642 me-
dium supplemented with 10% calf serum. Mouse lymph nodes (cervical,
axillary, inguinal, and mesenteric) were gently ground between the frosted
ends of microscope slides and filtered through nylon mesh, and adherent
cells were removed as above. BALB/c or C57BL/6 mice were used, as in-
dicated.
 
Chemotaxis
 
All migration assays were performed in 24-well plate tissue culture inserts
(Costar Corp., Cambridge, MA) with 5-
 
m
 
m pore polycarbonate filters. 5 
 
3
 
10
 
5
 
 cells were placed in the upper chamber in 100 
 
m
 
l, and 600 
 
m
 
l of a given
chemokine dilution in the lower well (unless otherwise indicated, as for
the checkerboard assays). Recombinant human and mouse 6CK/SLC
were obtained from R&D Systems (Minneapolis, MN). Synthetic human
MIP-3
 
b
 
 and SDF-1
 
a
 
 were synthesized by the authors (M.A. Siani and D.
Thomas, Gryphon Sciences) by chemical ligation (13). Human MIP-3
 
b
 
and SDF-1
 
a
 
 
 
were used for both the human and mouse systems since the
murine MIP-3
 
b
 
 
 
homologue has not yet been reported. The use of human
MIP-3
 
b
 
 on mouse lymphocytes is validated by its cross-reactivity with
mouse CCR7 (see Figs. 1 and 2), although the 
 
K
 
d
 
 may not be identical.
Human and mouse SDF-1
 
a
 
 differ by only two conservative amino acid
substitutions (35), and their activities are reportedly similar. Chemotaxis
medium consisted of RPMI-1642/10% calf serum for mouse lymphocytes
and L1/2 cells, and RPMI-1642/0.5%BSA Fr. V (Sigma Chemical Co., St.
Louis, MO) for human lymphocytes. Migration times were 30–60 min for
mouse lymphocytes, 90 min for human lymphocytes, and 3 h for L1/2 cells.
Migrated cells were counted as described (11, 12). All migration assays
were carried out at 37
 
8
 
C and 8% CO
 
2
 
.
Optimal chemotactic doses for each chemokine on each cell type were
determined by testing 10-fold dilutions between 1 
 
m
 
M and 1 nM. Twofold
dilutions were then carried out within the most effective decade. The opti-
mal chemotactic doses were: 100 nM for murine 6CK/SLC on mouse lym-
phocytes and L1/2 transfectants; 1 
 
m
 
M for human 6CK/SLC on human
lymphocytes and 100 nM on L1/2 transfectants; 50 nM for human SDF-1
 
a
 
on mouse lymphocytes and 100 nM on human lymphocytes; and 25 nM
human MIP-3
 
b
 
 on mouse lymphocytes, 100 nM on L1/2 transfectants, and
1 
 
m
 
M on human lymphocytes. 
 
Determination of Lymphocyte Subsets
 
The number of cells of each subtype was determined for the starting popu-
lation of each chemotactic assay. The number of cells belonging to the
same subtype was determined in the migrated population, and the percent
migration was determined from these two numbers. Six to eight wells
were chemotaxed for each chemokine, and the migrated cells were pooled
(after counting) to obtain sufficient cells for flow cytometry. Directly con-
jugated antibodies used in this study were obtained from PharMingen,
Inc. (San Diego, CA) unless otherwise indicated. Anti–mouse reagents:
FITC-conjugated CD8 (clone 53-6.7) and CD44 (clone MJ-64, grown and
conjugated by Butcher lab staff), APC-conjugated CD4 (clone GK1.5, a
generous gift of S. Michie, Stanford University, Stanford, CA), biotiny-
lated CD3
 
e
 
 (clone 145-2C11), and TCR
 
ab
 
 (clone H57-597). Anti–human
reagents: FITC-conjugated CD3 (clone UCHT1) and CD45RA (clone
HI100); PE-conjugated CD19 (clone B43), CD45RO (clone UCHL1), and
CD56 (clone B159); biotinylated CD4 (clone RPA-T4), CD8 (clone RPA-
T8), and CD16 (clone 3G8). The second stage reagent used for all biotiny-
lated antibodies was streptavidin-conjugated PerCP (Becton Dickinson,
San Jose, CA). Flow cytometry analysis was performed on a FACSCali-
bur
 
®
 
 driven by Cell Quest software (Becton Dickinson).
 
CCR7 Transfectants
 
L1/2 cells were stably transfected with epitope-tagged receptors as de-
scribed (10, 11, 16). The FLAGged muCCR7 cDNA was obtained from
BALB/c lymph node RNA using PCR primers based on GenBank acces-
sion number L31580 and inserted into a cytomegalovirus-driven vector
(pMRB-101). Human CCR7 (data available from GenBank/EMBL/DDBJ
under accession number L31581) cDNA was tagged at the NH
 
2
 
 terminus
with a hemagglutin in epitope (YPYDVPDYA) and subcloned into pCDNA3.
For transient transfections, L1/2 cells were cotransfected by electropora-
tion with these same constructs and the green fluorescent protein (GFP)
expression vector pGreen Lantern (GIBCO BRL, Gaithersburg, MD).
 
Receptor Binding Studies
 
Interaction of 6CK/SLC with a common lymphocyte receptor was as-
sessed by direct competition for radioactive MIP-3
 
b
 
 binding. Mouse
lymph node lymphocytes were incubated with 
 
125
 
I-MIP-3
 
b
 
 (obtained from
New England Nuclear [Boston, MA] and Amersham Corp. [Arlington
Heights, IL]; 0.2 nM) in the presence or absence of 200 nM cold MIP-3
 
b
 
,
6CK/SLC, or MCP-1 (R&D Systems). Chemokine binding to mouse lym-
phocytes was carried out using a modification of a method described pre-
viously (38). Briefly, mouse lymphocyte cells were prepared from lymph
nodes, washed, and resuspended in binding buffer (50 mM Hepes, pH 7.5,
1 mM CaCl
 
2
 
, 5 mM MgCl
 
2
 
, and 0.5% BSA) at 2 
 
3 
 
10
 
7
 
 cells/ml. For each
binding reaction (in a final volume of 100 ml), 25 
 
m
 
l of cell suspension (5 
 
3
 
10
 
5
 
 cells) was mixed with 0.2 nM labeled chemokine, in the presence or
absence of 200 nM unlabeled chemokines. The reactions were incubated 
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at room temperature for 60 min and stopped by transferring the mixture
to GFB filter plates, which were then washed three times with binding
buffer containing 0.5 M NaCl. The plates were dried, and MicroScint scin-
tillation fluid was added before counting. The bound radioactivity was de-
termined and used to calculate the percent inhibition by each of the com-
petitors. Two independent experiments were performed showing inhibition
by cold MIP-3
 
b
 
 and 6CK/SLC, each with duplicate or triplicate determi-
nations. MCP-1 inhibition was assessed in one experiment in triplicate. 
 
Results and Discussion
 
6CK/SLC Mediates Chemotaxis of CCR7 Transfectants
 
In a method described previously (10, 11, 16), L1/2 cells
(an Abelson-transformed murine pre-B cell line) were sta-
bly transfected with an epitope-tagged (FLAGged) ver-
sion of mouse CCR7 (Fig. 1). As expected, FLAGged
CCR7 transfectants, but not CCR1 transfectants, were at-
tracted efficiently to the known CCR7 ligand MIP-3
 
b
 
. As
shown in Fig. 1 
 
D
 
, mouse 6CK/SLC also attracted the
CCR7 transfectants, but not the CCR1 transfectants. 
When working with stably transfected cell lines, it is al-
ways formally possible that observed changes in cell be-
havior are brought about by selection pressures unrelated
(or only indirectly related) to the transfected gene. To
confirm that the 6CK/SLC-induced migration was medi-
ated by the transfected CCR7, transient transfections were
performed. Transient transfection of L1/2 cells creates
a heterogeneous population of receptor-expressing cells
successfully taking up and expressing transfected plasmid
(Fig. 2 
 
A
 
): In this system, cotransfected plasmids are co-
ordinately expressed (Bowman, E.P., unpublished data).
 
Cells transiently expressing transfected human or mouse
CCR7 sequences (GFP[
 
1
 
]) migrated efficiently towards
MIP-3
 
b
 
 and 6CK/SLC (Fig. 2 
 
C
 
), while those cells that did
not take up the electroporated DNA (GFP[
 
2
 
]) remained
unresponsive to these chemokines. We conclude that
CCR7 is a receptor for 6CK/SLC as well as for MIP-3
 
b
 
.
Importantly, CCR7, also known as EBI-1 or BLR-2 (3, 6),
is constitutively expressed at the Northern level in human
PBMC (3) and is highly represented in Southern blots of
complex cDNA libraries from L-selectin
 
1
 
 naive T cells
and Ig
 
1
 
 B cells from mouse spleen (Zlotnik, A., unpub-
lished data). CCR7 is thus likely to be a prominent recep-
tor for 6CK/SLC on circulating lymphocytes. 
 
MIP-3
 
b
 
, 
 
as well as 6CK/SLC, Is a Potent 
Chemoattractant for Resting Lymphocytes
 
We reasoned that if 6CK/SLC and MIP-3
 
b
 
 share CCR7
Figure 1. 6CK/SLC is a chemotactic agonist for the lymphocyte
chemokine receptor CCR7 (stable L1/2 transfectants). (A–C)
Anti-FLAG staining of Gia-linked receptor L1/2 transfectants.
Solid line, M1 anti-FLAG mAb; dotted line, isotype control.
Staining of (A) wild-type L1/2, (B) FLAGged CCR7 transfec-
tants, and (C) FLAGged CCR1 transfectants. (D) Chemotaxis of
L1/2 cells stably transfected with muCCR7 or hCCR1 to various
chemokines or control medium. Stably transfected cells were se-
lected to homogeneity by several rounds of sorting for the FLAG
epitope tag. Mean and range of duplicate wells is shown. Repre-
sentative of three individual experiments. 
Figure 2. 6CK/SLC is a chemotactic agonist for the lymphocyte
chemokine receptor CCR7 (transient CCR7 transfectants). (A
and B) GFP expression of transient CCR7 transfectants. (A)
hCCR7/GFP transient transfectants before chemotaxis (solid
line) overlaid on mock transfected control (dotted line). (B)
hCCR7/GFP transient transfectants after chemotaxis to h6CK/
SLC (solid line) overlaid on mock transfected control (dotted
line). (C) Chemotaxis of transient CCR7 transfectants. Cells were
transfected with either human or mouse CCR7 cDNA constructs
along with a GFP vector. 24 h after transfection, when the
chemotaxis was performed, the muCCR7 population was z25%
GFP(1), and the hCCR7 population was z42% GFP(1). For
each receptor/chemokine combination, chemotaxis was per-
formed in six replicate wells, and the number of migrated cells
enumerated as described previously (10, 11). Migrated cells in the
replicate wells of each receptor/chemokine combination were
then pooled and analyzed by flow cytometry for the frequency of
GFP-expressing (transfected) cells. The number of GFP(1) and
GFP(2) cells was determined for the starting population and for
each migrated population, and the percent migration was deter-
mined from these numbers. Maximum migration was 4.8% for
hCCR7 transfectants and 2.6% for muCCR7 transfectants. Mean
and range of duplicate wells are shown. Representative of two in-
dividual experiments.The Journal of Cell Biology, Volume 141, 1998 1056
as a prominent receptor on lymphocytes, then MIP-3b
should attract the major populations of circulating periph-
eral blood lymphocytes and mouse lymph node (LN) lym-
phocytes that respond to 6CK/SLC, including naive lym-
phocytes. Indeed, we found that the majority of both
human and mouse lymphocytes responding efficiently in
Transwell assays to MIP-3b, with chemotaxis comparable
to that of 6CK/SLC (Fig. 3). Checkerboard analyses con-
firmed that the responses to MIP-3b and 6CK/SLC were
chemotactic (not shown). Thus, both 6CK/SLC and MIP-
3b are not only potent adhesion-triggering chemokines for
most resting lymphocytes (12), but they are also potent cir-
culating lymphocyte chemoattractants. 
MIP-3b and 6CK/SLC Attract Similar Major 
Populations of Resting Human and Mouse Lymphocytes
The relative migration efficiency of various lymphocyte
types was determined by noting the number of each sub-
type in the starting population (as determined by flow cy-
tometry) and observing what percentage of this specific
population migrated to the bottom well in response to op-
timal chemotactic concentrations of MIP-3b, 6CK/SLC,
or, for comparison, SDF-1a. CD4(1) helper T cells form
the largest subpopulation of circulating human lympho-
cytes and can be divided into naive and memory pheno-
types based on their expression of CD45RA vs. CD45RO
(29). CD4(1) T cells are also a major subpopulation in
mouse lymph node, and naive vs. memory subpopulations
can be distinguished by relative CD44 levels in C57BL/6
mice (21). Both naive and memory helper T cells (Fig. 4)
were attracted efficiently to all three chemokines, as were
CD8(1) cytotoxic T and B cells. The NK population (de-
fined as CD3[2], CD56[1], and CD16[1]), however,
showed strong differences in its ability to respond to these
chemokines. This lymphocyte subset was only studied in
the human system, as it is not a major population in
healthy mouse lymph nodes. It is interesting to note that
the background migration of NK cells was higher than that
of any other population studied in this report (up to 20%
in some donors) and that NK cells comprised z80% of all
human lymphocytes that migrated in the absence of chemo-
kine in our system (not shown). Although the background
migration was high, a gradient of SDF-1a more than tri-
pled the number of migrating NK cells, whereas MIP-3b
and 6CK/SLC had no effect.
Thus, with the exception of NK cells (a population that
does not normally traffic through secondary lymphoid tis-
sue), MIP-3b and 6CK/SLC were potent attractors of each
of the major human and mouse lymphocyte subpopula-
tions. Different cell types were attracted with varying effi-
ciency. However, in our opinion, the quantitative differ-
ences in B vs. T cell chemotaxis to these chemokines in
vitro must be interpreted with caution since B cells also
migrate less efficiently in response to SDF-1a. In the ab-
sence of a “control” B cell attractant that recruits the ma-
jority of B cells across Transwell membranes, one cannot
exclude that mechanical limitations (e.g., deformability) or
other cell properties limit in vitro B cell responses. On the
other hand, additional chemokines may support B cell re-
cruitment, and it is also worth pointing out that B cell re-
circulation is in general slower than that of T cells in vivo,
as well. 
It is interesting to note that the optimal chemotactic
doses of MIP-3b and 6CK/SLC differed by 10-fold be-
tween human circulating lymphocytes and mouse lymph
node lymphocytes in our system. However, when human
or mouse CCR7 were expressed in L1/2 cells, the optimal
chemotactic doses were indistinguishable (100 nM, similar
to those for mouse lymph node cells). This suggests that
the cellular environment in which the receptor is ex-
pressed may influence its interaction with ligand and/or its
signaling.
MIP-3b Inhibits Lymphocyte Chemotaxis to 6CK/SLC 
but Not to SDF-1
Cross-desensitization assays are an established tool for as-
sessing common receptor usage by chemokines: Binding of
agonist to chemokine receptors induces rapid homologous
desensitization, inhibiting responses to other agonists act-
ing through the same receptor, but not to those interacting
with independent receptors (for review see reference 1).
Therefore, we postulated that if 6CK/SLC acts primarily
through the MIP-3b receptor on lymphocytes, then MIP-3b
preincubation should inhibit its activity. The mouse system
Figure 3. MIP-3b, like 6CK/SLC, is a po-
tent attractant for resting human and
mouse lymphocytes. (A) Migration of
freshly isolated human circulatory lym-
phocytes through 5-mm pores for 90 min.
The optimal chemotactic dose was used
for each chemokine (see Materials and
Methods). Medium, the number of cells
migrating into the bottom well in the ab-
sence of chemokine. Mean of two experi-
ments (eight wells each) with individual
healthy donors is shown; error bars indi-
cate range. (B) Migration of freshly iso-
lated mouse lymph node lymphocytes for
60 min through 5-mm pores. The optimal
chemotactic dose was used. Mean of two
experiments with different mouse strains
(BALB/c and C57BL/6) is shown; error
bars indicate range. Campbell et al. 6CK/SLC and MIP-3b Share a Common Receptor 1057
was used for these studies because much lower concentra-
tions of chemokines were needed for optimal chemotaxis
to 6CK/SLC and MIP-3b than were required for the hu-
man system (see Materials and Methods).
Mouse lymphocytes were treated for 30 min with MIP-3b
(at 53 the optimal chemotactic dose) or control medium,
washed quickly by centrifugation through a layer of serum,
and then immediately placed in a chemotaxis assay. Abil-
ity to migrate towards an optimal concentration of 6CK/
SLC was then tested. The desensitization process did not
appreciably increase background migration (not shown).
MIP-3b quite effectively desensitized migration to 6CK/
SLC, whereas the response to SDF-1a (which acts through
an independent receptor CXCR4; references 4, 26) was not
inhibited (Fig. 5). Similarly, 6CK/SLC preincubation abro-
gated lymphocyte chemotaxis to MIP-3b. In contrast, prein-
cubation with SDF-1a inhibited its own responses, with
only minor effects on migration to the CCR7 agonists.
6CK/SLC Inhibits MIP-3b Binding to Lymphocytes
We reasoned that if CCR7 is a prominent receptor for
6CK/SLC and MIP-3b on lymphocytes, then 6CK/SLC
should inhibit MIP-3b binding to the lymphocyte surface.
Mouse lymph node cells bound 125I–MIP-3b, and this bind-
ing was significantly inhibited by excess cold MIP-3b (62
and 78% in two separate experiments) and to a similar ex-
tent by 6CK/SLC (69 and 73%). In contrast, cold MCP-1
had no significant effect. Thus, the predominant MIP-3b
receptor on resting lymphocytes is shared by 6CK/SLC. 
Our results demonstrate that two major lymphocyte
chemoattractants of lymphoid tissues—6CK/SLC, ex-
pressed by HEV(15), and MIP-3b, also prominently ex-
pressed in LN, Peyer’s patch (PP), and spleen (27, 39)—
share a common receptor and attract the major circulating
lymphocyte subsets that traffic through secondary lym-
phoid organs. Both chemokines are potent attractants for
naive T cells, but also recruit memory CD4(1) T cells and
CD8(1) T cells and B cells, all populations that enter lym-
phoid tissues via HEV with varying efficiency (8, 9, 22, 33,
37). Although murine MIP-3b protein was not available
for these experiments, a mouse sequence with 74% amino
acid identity to human MIP-3b is found in the EST data-
base (available from GenBank/EMBL/DDBJ under ac-
cession number AA444730), suggesting that a mouse ver-
sion of MIP-3b protein does indeed exist in vivo. In light
of the functional similarities between 6CK/SLC and MIP-
3b, including preferential, high levels of mRNA expres-
sion in secondary lymphoid organs as well as shared recep-
tor usage and chemoattractant activity for lymphocytes as
shown here, it is of interest that these two CC chemokines
share a common chromosomal location (24). Thus, even
though they display only 33% amino acid identity in the
chemokine domain, they may well have arisen from a rela-
tively recent common lymphocyte chemoattractant pre-
cursor. The evolutionary advantage of having two related
agonists for CCR7 is unclear at present, but such promis-
cuity is not uncommon among the chemokines and their
receptors (1, 29). It will be of interest to determine the ex-
tent of specialization between 6CK/SLC and MIP-3b in
controlling lymphocyte migration into and within lym-
phoid organs, and to ask how such specialization relates to
the clear structural differences between them, especially
the 38–amino acid COOH-terminal extension of 6CK/
SLC. Since 6CK/SLC is abundantly expressed by HEV by
in situ analyses, one can postulate that its COOH-terminal
Figure 4. MIP-3b and 6CK/SLC attract similar lymphocyte subpopulations. (Top row) Percent migration of resting human peripheral
blood lymphocytes. Subsets defined by multiparameter FACS® analysis as follows: natural killer 5 CD3(2), CD56(1), CD16(1); naive
CD4(1)  5  CD4(1), CD45RA(1), CD45RO(2); memory CD4(1) 5 CD4(1), CD45RA(2), CD45RO(1); CD8(1) T cells 5
CD3(1), CD8(1); B cells 5 CD3(2), CD19(1). Migration through 5-mm pores for 90 min. Mean of two experiments (eight wells each)
with individual healthy donors is shown; error bars indicate range. (Bottom row) Percent migration of resting mouse lymphocytes de-
fined as follows: naive CD4(1) 5 CD3(1), CD4(1), CD44(lo); memory CD4(1) 5 CD3(1), CD4(1), CD44(hi); CD8(1) T cells 5
TCRab(1), CD8(1); B cells 5 TCRab(2), B220(1). Migration through 5-mm pores for 60 min. Mean of two individual experiments
(six wells each) with 20-wk C57BL/6 is shown; error bars indicate range.The Journal of Cell Biology, Volume 141, 1998 1058
extension may have a role in stabilizing or facilitating its
presentation at the vascular lumen, where it may help trig-
ger b2 integrin–dependent lymphocyte arrest. 
Recent studies show that 6CK/SLC can also signal
through CXCR3, a receptor that also supports chemotaxis
to the a chemokines MIG and IP-10 (Zlotnik, A., unpub-
lished data). Importantly, responses to MIG and IP-10 are
reported to be predominantly limited to in vitro–activated
T cells, with little effect on the bulk of freshly isolated
PBL (20, 23). Moreover, MIP-3b does not signal though
CXCR3. Thus, CXCR3 may contribute to the migration of
activated T cells in vivo, but is unlikely to play a significant
role in the major, especially naive, B and T cell responses
to 6CK/SLC and MIP-3b discussed here. 
It is important to consider the potential contribution of
chemokines to the specificity of lymphocyte trafficking in
the context of the specialized selectin, integrin, and other
adhesion/homing receptors involved. As mentioned in the
introduction, although most circulating white blood cells
express L-selectin and b2 integrins required for rolling
and arrest in lymph node HEV (36), and eosinophils and
subsets of NK cells, at least, also display the a4b7 inte-
grin intestinal homing receptor involved in homing to
Peyer’s patches, these cells do not normally enter LN or
PP efficiently from the blood in the absence of significant
inflammation. Such observations, in fact, led to the initial
hypothesis of a generalized multistep model of leukocyte–
endothelial recognition, in which an essential, rapid activa-
tion event required for integrin-mediated adhesion was
postulated to control specificity of lymphocyte (vs. mono-
cyte and granulocyte) arrest in HEV (7). In this context,
the apparent selectivity of 6CK/SLC and MIP-3b for recir-
culating lymphocyte populations, and their lack of activity
on monocytes, neutrophils, and NK cells, would allow
them to make a critical contribution to the selectivity of
lymphocyte–HEV recognition. On the other hand, each of
these chemokines appears to be expressed in both intesti-
nal (PP, appendix) and peripheral (LN, spleen) lymphoid
organs (15, 17, 24, 27, 39). Thus, while they may permit
lymphocyte but not other leukocyte arrest in these sites,
differential adhesion/homing receptor requirements (e.g.,
a4b7-MAdCAM-1 in PPs) may remain the primary deter-
minants for the targeted homing and segregation of intes-
tinal vs. peripheral memory lymphocytes to PPs vs. periph-
eral lymphoid tissues (8).
Finally, the finding that CCR7 is a shared receptor for
the HEV-expressed chemokine 6CK/SLC, as well as for
MIP-3b, suggests that it may itself be an important lym-
phocyte “homing receptor” for secondary lymphoid or-
gans. In vivo studies will be required, however, to explore
further the involvement of CCR7 in physiological lympho-
cyte trafficking, to elucidate the relative contributions of
6CK/SLC and MIP-3b, and to define their roles in physio-
logical lymphocyte recirculation and in lymphocyte hom-
ing during pathological inflammation.
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Note Added in Proof. Since submission of this manuscript, Kim et al. (J.
Immunol. 1998. 160:2418) have reported that MIP-3b (CKb-11) induced
chemotaxis of blood B and T cells, and Yoshida et al. (J. Biol. Chem. 1998.
273:7118) have confirmed that CCR7 is a receptor of 6CK/SLC.
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